Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 441

Similar articles for PubMed (Select 19130617)

1.

Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study.

Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, Bisaccia E, Goerdt S, Hanauer S, Knobler R, Mannon P, Mayer L, Ochsenkuhn T, Sandborn WJ, Parenti D, Lee K, Reinisch W; Crohn's Disease Photopheresis Study Group.

Inflamm Bowel Dis. 2009 Jun;15(6):829-36. doi: 10.1002/ibd.20833.

PMID:
19130617
2.

Extracorporeal photochemotherapy for the treatment of refractory Crohn's disease.

Bisaccia E, Palangio M, Gonzalez J.

Transfus Apher Sci. 2007 Oct;37(2):171-4. Epub 2007 Nov 13.

PMID:
17993292
3.
4.

Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohn's disease: an open-label, multicenter, prospective trial.

Reinisch W, Knobler R, Rutgeerts PJ, Ochsenkühn T, Anderson F, von Tirpitz C, Kaatz M, Janneke van der Woude C, Parenti D, Mannon PJ.

Inflamm Bowel Dis. 2013 Feb;19(2):293-300. doi: 10.1002/ibd.23012.

5.
6.

Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease.

Sands BE, Sandborn WJ, Wolf DC, Katz S, Safdi M, Schwartz DA, Hanauer SB.

J Clin Gastroenterol. 2006 Jul;40(6):482-9.

PMID:
16825929
7.

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan SR.

Gastroenterology. 1999 Dec;117(6):1278-87.

PMID:
10579968
8.

A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.

Dotan I, Rachmilewitz D, Schreiber S, Eliakim R, van der Woude CJ, Kornbluth A, Buchman AL, Bar-Meir S, Bokemeyer B, Goldin E, Maaser C, Mahadevan U, Seidler U, Hoffman JC, Homoky D, Plasse T, Powers B, Rutgeerts P, Hommes D; Semapimod-CD04/CD05 Investigators.

Gut. 2010 Jun;59(6):760-6. doi: 10.1136/gut.2009.179994.

PMID:
20551461
9.

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB.

Gastroenterology. 1999 Dec;117(6):1271-7.

PMID:
10579967
10.

Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial.

D'Haens G, Swijsen C, Noman M, Lemmens L, Ceuppens J, Agbahiwe H, Geboes K, Rutgeerts P.

Am J Gastroenterol. 2001 Sep;96(9):2564-8.

PMID:
11569676
11.

6-thioguanine--efficacy and safety in chronic active Crohn's disease.

Herrlinger KR, Kreisel W, Schwab M, Schoelmerich J, Fleig WE, Ruhl A, Reinshagen M, Deibert P, Fellermann K, Greinwald R, Stange EF.

Aliment Pharmacol Ther. 2003 Feb 15;17(4):503-8.

12.

Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease.

Cassinotti A, Annaloro C, Ardizzone S, Onida F, Della Volpe A, Clerici M, Usardi P, Greco S, Maconi G, Porro GB, Deliliers GL.

Gut. 2008 Feb;57(2):211-7. Epub 2007 Sep 25.

PMID:
17895357
13.

An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.

Sabate JM, Villarejo J, Lemann M, Bonnet J, Allez M, Modigliani R.

Aliment Pharmacol Ther. 2002 Jun;16(6):1117-24.

14.

Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study.

González-Lama Y, Abreu L, Vera MI, Pastrana M, Tabernero S, Revilla J, Durán JG, Escartin P.

Inflamm Bowel Dis. 2005 Jan;11(1):8-15.

PMID:
15674108
15.

An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease.

Korzenik JR, Dieckgraefe BK.

Aliment Pharmacol Ther. 2005 Feb 15;21(4):391-400.

16.

Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease.

Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG; Teduglutide Study Group.

Inflamm Bowel Dis. 2010 Jun;16(6):962-73. doi: 10.1002/ibd.21117.

PMID:
19821509
17.

Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.

Thia KT, Sandborn WJ, Lewis JD, Loftus EV Jr, Feagan BG, Steinhart AH, Hanauer SB, Persson T, Sands BE.

Am J Gastroenterol. 2008 Dec;103(12):3123-31. doi: 10.1111/j.1572-0241.2008.02176.x.

PMID:
18786111
18.

Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.

Sands BE, Winston BD, Salzberg B, Safdi M, Barish C, Wruble L, Wilkins R, Shapiro M, Schwertschlag US; RHIL-11 Crohn's Study group.

Aliment Pharmacol Ther. 2002 Mar;16(3):399-406.

19.

An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.

Sandborn WJ, Hanauer S, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R.

Am J Gastroenterol. 2004 Oct;99(10):1984-9.

PMID:
15447761
20.

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group.

Gastroenterology. 2007 May;132(5):1672-83. Epub 2007 Mar 21.

PMID:
17484865
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk